Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1/2 trial
2024; Elsevier BV; Volume: 11; Issue: 6 Linguagem: Inglês
10.1016/s2352-3026(24)00078-4
ISSN2451-9960
AutoresBanu Aygün, Adam Lane, Luke R. Smart, Brígida Santos, Léon Tshilolo, Thomas N. Williams, Peter Olupot‐Olupot, Susan E. Stuber, George Tomlinson, Teresa S. Latham, Russell E. Ware,
Tópico(s)Myeloproliferative Neoplasms: Diagnosis and Treatment
ResumoRealizing Effectiveness Across Continents with Hydroxyurea (REACH) is an open-label non-randomised trial of hydroxyurea (hydroxycarbamide) in children with sickle cell anaemia in sub-Saharan Africa. The short-term results of REACH on safety, feasibility, and effectiveness of hydroxyurea were published previously. In this paper we report results from extended hydroxyurea treatment in the REACH cohort up to 8 years.
Referência(s)